期刊
GASTROENTEROLOGY
卷 162, 期 5, 页码 1507-1511出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2021.09.078
关键词
Inflammatory Bowel Disease; Early Diagnosis; Clin-ical Trials; Quality of Care; Biomarkers
资金
- AbbVie
- Arena
- Aslan
- AstraZeneca
- BMS
- Celegne
- Ferring
- Galapagos
- Gilead
- GSK
- Heptares
- LabGenius
- Janssen
- Mylan
- MSD
- Novartis
- Pfizer
- Sandoz
- Takeda
- UCB
There is a high level of uncertainty in the treatment response for patients starting a new treatment for inflammatory bowel disease. To overcome the current limitations, improvements are needed in areas such as diagnosis, treatment stratification, response monitoring, and clinical trial design.
Outcomes for patients starting a new treatment for inflammatory bowel disease are characterized by uncertainty of treatment response. Although it is natural to hope that new treatments will be characterized by better efficacy, remission is still far from a universal experience for patients living with inflammatory bowel disease. At times, an apparent glass ceiling appears to constrain progress toward a goal of maximal long-term health care-related quality of life for all. There are a number of areas that can and should be addressed if we are to make significant progress. These range from improved early diagnosis and initial management through better treatment stratification and response monitoring, to improvements in clinical trial design and selection of drugs in combination therapies. In this article, we discuss the steps required in all of these areas to make best use of new therapeutic options and shatter the glass ceiling.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据